drugset / Trial / NCT06550232

IV PAPAVERINE Prior to Propess for Labor Induction

NCT06550232

Phase 4 Completed 110 enrolled Western Galilee Hospital-Nahariya
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators aim to evaluate the effect of administering papaverine prior to PGE2 insertion on changes in Bishop-scores and on the induction-to-delivery interval. Researchers will compare drug papaverine to a placebo

Timeline

Start
2024-08-12
Primary completion
2025-03-23
Completion
2025-03-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Papaverine Small molecule 80 mg Intravenous

Indications

No indication recorded.